Jasper Therapeutics to Speak at Jefferies Global Healthcare Conference

REDWOOD CITY, Calif., May 29, 2024 – Jasper Therapeutics (Nasdaq: JSPR), a biotechnology company pioneering the development of briquilimab, an innovative antibody treatment targeting c-Kit (CD117), is set to present at the Jefferies Global Healthcare Conference. The presentation will take place at 4:00 PM EDT on Wednesday, June 5, 2024. A live webcast will be accessible on the Jasper Investor Relations website, with a replay available for 30 days post-event.

About Jasper Therapeutics

Jasper Therapeutics is a biotechnology firm in the clinical stages of developing briquilimab, a monoclonal antibody directed at c-Kit (CD117). This novel therapy is aimed at treating chronic mast and stem cell disorders, including chronic urticaria and myelodysplastic syndromes (MDS). Additionally, briquilimab is being explored as a conditioning agent for stem cell transplants in rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA), and severe combined immunodeficiency (SCID). The efficacy and safety of briquilimab have been demonstrated in over 145 participants and healthy volunteers, particularly as a conditioning agent for SCID, acute myeloid leukemia, MDS, FA, and SCD.

Risk Factors

Jasper faces several risks that could affect actual results, including:
- General economic, political, and business conditions.
- Delays or failures in clinical development and regulatory approval of product candidates.
- Inconsistent clinical trial results regarding safety and efficacy.
- Market acceptance challenges and competition.
- Dependence on third-party services for clinical development and manufacturing.
- Potential impacts from health epidemics on business operations and supply chains.
- Intellectual property protection challenges.

For a detailed discussion of these risks, refer to Jasper's filings with the SEC, including their Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Jasper disclaims any obligation to update forward-looking statements, which should not be relied upon as current assessments beyond the press release date.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!